<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
</style>
</head><body>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Call Start: 09:00 January 1, 0000 9:49 AM ET<br><br>Humana, Inc. (NYSE:HUM)<br>Q4 2024 Earnings Conference Call<br>February 11, 2025, 09:00 ET<br><br>Company Participants<br><br>Lisa Stoner - VP, IR<br>James Rechtin - President, CEO & Director<br>Celeste Mellet - CFO<br>George Renaudin - President, Insurance<br><br>Conference Call Participants<br><br>Ann Hynes - Mizuho<br>Justin Lake - Wolfe Research<br>Sarah James - Cantor Fitzgerald<br>Joshua Raskin - Nephron Research<br>A.J. Rice - UBS<br>Ben Hendrix - RBC Capital Markets<br>Whit Mayo - Leerink Partners<br>Erin Wright - Morgan Stanley<br>Scott Fidel - Stephens<br>George Hill - Deutsche Bank<br>Ryan Langston - TD Cowen<br>Andrew Mok - Barclays<br><br>Operator<br><br>Good day, and thank you for standing by.</td><td>í†µí™” ì‹œì‘: 2025ë…„ 1ì›” 1ì¼ ì˜¤ì „ 9ì‹œ 49ë¶„ ET<br><br>íœ´ë§ˆë‚˜, Inc. (NYSE:HUM)<br>2024ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ<br>2025ë…„ 2ì›” 11ì¼, ì˜¤ì „ 9ì‹œ ET<br><br>íšŒì‚¬ ì°¸ê°€ì<br><br>ë¦¬ì‚¬ ìŠ¤í† ë„ˆ - IR ë¶€ì‚¬ì¥<br>ì œì„ìŠ¤ ë ‰í‹´ - íšŒì¥, CEO & ì´ì‚¬<br>ì…€ë ˆìŠ¤íŠ¸ ë©œë › - CFO<br>ì¡°ì§€ ë¥´ë…¸ë”˜ - ë³´í—˜ ë¶€ë¬¸ íšŒì¥<br><br>ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ê°€ì<br><br>ì•¤ í•˜ì¸ì¦ˆ - ë¯¸ì¦ˆí˜¸<br>ì €ìŠ¤í‹´ ë ˆì´í¬ - ìš¸í”„ ë¦¬ì„œì¹˜<br>ì‚¬ë¼ ì œì„ìŠ¤ - ìº”í„° í”¼ì¸ ì œëŸ´ë“œ<br>ì¡°ìŠˆì•„ ë¼ìŠ¤í‚¨ - ë„¤í”„ë¡  ë¦¬ì„œì¹˜<br>A.J. ë¼ì´ìŠ¤ - UBS<br>ë²¤ í—¨ë“œë¦­ìŠ¤ - RBC ìºí”¼íƒˆ ë§ˆì¼“<br>íœ« ë©”ì´ìš” - ë¦¬ì–´ë§í¬ íŒŒíŠ¸ë„ˆìŠ¤<br>ì—ë¦° ë¼ì´íŠ¸ - ëª¨ê±´ ìŠ¤íƒ ë¦¬<br>ìŠ¤ì½§ í”¼ë¸ - ìŠ¤í…ŒíŒìŠ¤<br>ì¡°ì§€ í - ë„ì´ì¹˜ ë±…í¬<br>ë¼ì´ì–¸ ë­ìŠ¤í„´ - TD ì¹´ìš°ì—”<br>ì•¤ë“œë¥˜ ëª© - ë°”í´ë ˆì´ìŠ¤<br><br>ì§„í–‰ì<br><br>ì—¬ëŸ¬ë¶„, ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ? ì˜¤ëŠ˜ í†µí™”ì— ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Welcome to Humana's Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to Lisa Stoner, Vice President, Investor Relations. Please go ahead. Lisa Stoner<br><br>Thank you, and good morning. I hope everyone had a chance to review our press release and prepared remarks, which are available on our website.</td><td>ë‹¤ìŒì€ íœ´ë§ˆë‚˜ì˜ 2024ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. [ìš´ì˜ì ì•ˆë‚´] ì˜¤ëŠ˜ì˜ ì»¨í¼ëŸ°ìŠ¤ëŠ” ë…¹ìŒë˜ê³  ìˆìŒì„ ì•Œë ¤ë“œë¦½ë‹ˆë‹¤. ì´ì œ íˆ¬ìì ê´€ê³„ ë¶€ì‚¬ì¥ì¸ ë¦¬ì‚¬ ìŠ¤í† ë„ˆì—ê²Œ íšŒì˜ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ì§„í–‰í•´ ì£¼ì„¸ìš”, ë¦¬ì‚¬ ìŠ¤í† ë„ˆ.<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, ê·¸ë¦¬ê³  ì¢‹ì€ ì•„ì¹¨ì…ë‹ˆë‹¤. ì—¬ëŸ¬ë¶„ ëª¨ë‘ ì €í¬ê°€ ì›¹ì‚¬ì´íŠ¸ì— ê²Œì‹œí•œ ë³´ë„ ìë£Œì™€ ì¤€ë¹„ëœ ë°œì–¸ì„ ê²€í† í•  ê¸°íšŒê°€ ìˆì—ˆê¸°ë¥¼ ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>We will begin this morning with brief remarks from Jim Rechtin, Humana's President and Chief Executive Officer; and Chief Financial Officer, Celeste Mellet, which will be followed by a Q&A session, where Jim and Celeste will be joined by George Renaudin, President of Humana's Insurance segment. Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward-looking and involve a number of risks and uncertainties. Actual results could differ materially.</td><td>ì˜¤ëŠ˜ ì•„ì¹¨ì€ íœ´ë§ˆë‚˜ì˜ ëŒ€í‘œì´ì‚¬ ê²¸ ìµœê³ ê²½ì˜ìì¸ ì§ ë ‰í‹´ê³¼ ìµœê³ ì¬ë¬´ì±…ì„ì ì…€ë ˆìŠ¤íŠ¸ ë©œë ›ì˜ ê°„ëµí•œ ë°œì–¸ìœ¼ë¡œ ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ì´ì–´ì„œ ì§ˆì˜ì‘ë‹µ ì„¸ì…˜ì´ ì§„í–‰ë  ì˜ˆì •ì´ë©°, ì´ë•Œ ì§ê³¼ ì…€ë ˆìŠ¤íŠ¸ëŠ” íœ´ë§ˆë‚˜ ë³´í—˜ ë¶€ë¬¸ì˜ ëŒ€í‘œ ì¡°ì§€ ë¥´ë…¸ë”˜ê³¼ í•¨ê»˜í•  ê²ƒì…ë‹ˆë‹¤. í† ë¡ ì„ ì‹œì‘í•˜ê¸° ì „ì—, ì°¸ê°€ì ì—¬ëŸ¬ë¶„ê»˜ ì£¼ì˜ì‚¬í•­ì„ ì•Œë ¤ë“œë¦´ í•„ìš”ê°€ ìˆìŠµë‹ˆë‹¤. ì´ë²ˆ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œ ë…¼ì˜ë˜ëŠ” ì¼ë¶€ ì‚¬í•­ì€ ì „ë§ì„±ì„ ê°€ì§€ê³  ìˆìœ¼ë©°, ì—¬ëŸ¬ ìœ„í—˜ê³¼ ë¶ˆí™•ì‹¤ì„±ì„ í¬í•¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‹¤ì œ ê²°ê³¼ëŠ” ìƒë‹¹íˆ ë‹¬ë¼ì§ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Investors are advised to read the detailed risk factors discussed in our latest Form 10-K, our other filings with the Securities and Exchange Commission, and our fourth quarter 2024 earnings press release, as they relate to forward-looking statements along with other risks discussed in our SEC filings. We undertake no obligation to publicly address or update any forward-looking statements and future filings or communications regarding our business or results. Today's press release, our historical financial news releases and our filings with the SEC are all also available on our Investor Relations site.</td><td>íˆ¬ìì ì—¬ëŸ¬ë¶„ê»˜ì„œëŠ” ë‹¹ì‚¬ì˜ ìµœì‹  Form 10-K, ë¯¸êµ­ ì¦ê¶Œê±°ë˜ìœ„ì›íšŒ(SEC)ì— ì œì¶œí•œ ê¸°íƒ€ ì„œë¥˜ë“¤, ê·¸ë¦¬ê³  2024ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ìë£Œë¥¼ ì°¸ì¡°í•˜ì‹œì–´, ì „ë§ì„ ë‹´ì€ ì„±ëª…ê³¼ ê´€ë ¨ëœ ìƒì„¸í•œ ìœ„í—˜ ìš”ì†Œë“¤ì„ ê¼¼ê¼¼íˆ ì½ì–´ë³´ì‹œê¸° ë°”ëë‹ˆë‹¤. ì´ ë¬¸ì„œë“¤ì€ SEC ì œì¶œ ì„œë¥˜ì— ë…¼ì˜ëœ ê¸°íƒ€ ìœ„í—˜ë“¤ê³¼ë„ ê´€ë ¨ì´ ìˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ê³µê°œì ìœ¼ë¡œ ì „ë§ ì„±ëª…ì„ ìˆ˜ì •í•˜ê±°ë‚˜ ì—…ë°ì´íŠ¸í•  ì˜ë¬´ê°€ ì—†ìœ¼ë©°, í–¥í›„ ì‚¬ì—… ê²°ê³¼ë‚˜ ì»¤ë®¤ë‹ˆì¼€ì´ì…˜ì— ê´€í•œ ì„œë¥˜ ì œì¶œ ì‹œì—ë„ ì´ë¥¼ ë°˜ì˜í•  ì˜ë¬´ê°€ ì—†ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ì˜ ë³´ë„ ìë£Œ, ê³¼ê±°ì˜ ì¬ë¬´ ê´€ë ¨ ë³´ë„ ìë£Œ ë° SECì— ì œì¶œëœ ì„œë¥˜ëŠ” ëª¨ë‘ ë‹¹ì‚¬ì˜ íˆ¬ìì ê´€ê³„ ì‚¬ì´íŠ¸ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Call participants should note that today's discussion includes financial measures that are not in accordance with generally accepted accounting principles, or GAAP. Management's explanation for the use of these non-GAAP measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release. Any references to earnings per share, or EPS, made during this conference call refer to diluted earnings per common share. Finally, this call is being recorded for replay purposes. That replay will be available on the Investor Relations page of Humana's website, humana.com, later today. With that, I'll turn the call over to Jim Rechtin.</td><td>ì°¸ì„ì ì—¬ëŸ¬ë¶„ê»˜ ì•Œë ¤ë“œë¦½ë‹ˆë‹¤. ì˜¤ëŠ˜ ë…¼ì˜ë  ë‚´ìš©ì—ëŠ” ì¼ë°˜ì ìœ¼ë¡œ ì¸ì •ëœ íšŒê³„ ì›ì¹™, ì¦‰ GAAPì— ë¶€í•©í•˜ì§€ ì•ŠëŠ” ì¬ë¬´ ì§€í‘œë“¤ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë¹„GAAP ì§€í‘œë¥¼ ì‚¬ìš©í•˜ëŠ” ì´ìœ ì™€ GAAPì—ì„œ ë¹„GAAP ì¬ë¬´ ì§€í‘œë¡œì˜ ì¡°ì • ë‚´ìš©ì€ ì˜¤ëŠ˜ ë°œí‘œëœ ë³´ë„ìë£Œì— í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì´ë²ˆ ì»¨í¼ëŸ°ìŠ¤ ì½œ ë™ì•ˆ ì–¸ê¸‰ë˜ëŠ” ì£¼ë‹¹ìˆœì´ìµ, ì¦‰ EPSëŠ” í¬ì„ëœ ì£¼ë‹¹ìˆœì´ìµì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ì´ í†µí™”ëŠ” ì¬ìƒ ëª©ì ìœ¼ë¡œ ë…¹ìŒë˜ê³  ìˆìœ¼ë©°, í•´ë‹¹ ë…¹ìŒì€ ì˜¤ëŠ˜ ë‚˜ì¤‘ì— Humanaì˜ ì›¹ì‚¬ì´íŠ¸, humana.comì˜ íˆ¬ìì ê´€ê³„ í˜ì´ì§€ì—ì„œ ë“¤ìœ¼ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ì œ ì§ ë ‰í‹´ì—ê²Œ ì—°ê²°í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">Humana, Inc. (NYSE:HUM) held its Q4 2024 earnings conference call on February 11, 2025. The call included brief remarks from President and CEO Jim Rechtin and CFO Celeste Mellet, followed by a Q&A session. Key participants were informed of forward-looking statements and associated risks, as detailed in Humana's SEC filings and earnings press release. The discussion also included non-GAAP financial measures, with reconciliations provided in the press release. The call, recorded for replay, is available on Humana's Investor Relations website.</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Question-and-Answer Session<br><br>Operator<br><br>Our first question comes from Ann Hynes with Mizuho. Ann Hynes<br><br>Can you hear me? Lisa Stoner<br><br>Yes. Ann Hynes<br><br>I just want to focus on 2025 MLR guidance. Can you just break down the levers of the increase, what is -- what base you're assuming? What's the overall cost trend? How much is driven by IRA changes and what the impact of the greater-than-expected loss of D-SNP MLR, that would be great. Celeste Mellet<br><br>Ann, it's Celeste. Thanks for your question. So to give you some additional color on top of what we included in our prepared remarks. First, I'll give you the drivers of the decreases in the ratio, which are improving the ratio.</td><td>ì§ˆì˜ì‘ë‹µ ì„¸ì…˜<br><br>ì§„í–‰ì<br><br>ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ Mizuhoì˜ Ann Hynesë¡œë¶€í„°ì…ë‹ˆë‹¤. Ann Hynes<br><br>ì € ë“¤ë¦¬ì„¸ìš”? Lisa Stoner<br><br>ë„¤. Ann Hynes<br><br>2025ë…„ MLR(ì˜ë£Œ ì†ì‹¤ ë¹„ìœ¨) ê°€ì´ë“œë¼ì¸ì— ì§‘ì¤‘í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ì¦ê°€ì˜ ë ˆë²„ë¥¼ êµ¬ì²´ì ìœ¼ë¡œ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ì–´ë–¤ ê¸°ì¤€ì„ ê°€ì •í•˜ê³  ê³„ì‹ ê°€ìš”? ì „ë°˜ì ì¸ ë¹„ìš© ì¶”ì„¸ëŠ” ì–´ë–»ìŠµë‹ˆê¹Œ? IRA ë³€ê²½ìœ¼ë¡œ ì¸í•œ ì˜í–¥ì€ ì–¼ë§ˆë‚˜ ë˜ë©°, ì˜ˆìƒë³´ë‹¤ í° D-SNP MLR ì†ì‹¤ì˜ ì˜í–¥ì€ ì–´ë–»ìŠµë‹ˆê¹Œ? Celeste Mellet<br><br>ì•¤, Celesteì…ë‹ˆë‹¤. ì§ˆë¬¸í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì¤€ë¹„ëœ ë°œì–¸ì— ë§ë¶™ì—¬ ì¢€ ë” êµ¬ì²´ì ì¸ ì •ë³´ë¥¼ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¨¼ì €, ë¹„ìœ¨ ê°ì†Œë¥¼ ì´ë„ëŠ” ìš”ì¸ë“¤ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ëŠ” ë¹„ìœ¨ì„ ê°œì„ í•˜ëŠ” ë° ë„ì›€ì´ ë©ë‹ˆë‹¤.</td></tr>
<tr><td>First, the majority of the improvement is driven from the MA plan exits, which all had very high benefit ratios. We also made other adjustments to our benefits in our remaining plans, which also improved the ratio. And then finally, the favorable calendar in 2025, given both how the days fall and the extra day in 2024 due to the leap year. Second, the increases to the ratio, which are a drag. First, business mix changes given Medicaid is growing. Medicaid carries a higher benefit ratio versus MA, as you know. Second, the IRA impact, which increases the benefit ratio given increased revenue with offsetting increases in claims.</td><td>ìš°ì„ , ëŒ€ë¶€ë¶„ì˜ ê°œì„ ì€ í˜œíƒ ë¹„ìœ¨ì´ ë§¤ìš° ë†’ì•˜ë˜ MA ê³„íšì˜ ì¢…ë£Œì—ì„œ ë¹„ë¡¯ë˜ì—ˆìŠµë‹ˆë‹¤. ë˜í•œ ë‚¨ì•„ ìˆëŠ” ê³„íšì—ì„œ í˜œíƒì„ ì¡°ì •í•˜ì—¬ ë¹„ìœ¨ì„ ê°œì„ í•˜ì˜€ìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ 2025ë…„ì˜ ìœ ë¦¬í•œ ë‹¬ë ¥ì´ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ë‚ ì§œê°€ ì–´ë–»ê²Œ ë°°ì¹˜ë˜ì—ˆëŠ”ì§€ì™€ 2024ë…„ ìœ¤ë…„ìœ¼ë¡œ ì¸í•œ ì¶”ê°€ ì¼ìˆ˜ ë•Œë¬¸ì…ë‹ˆë‹¤. ë‘ ë²ˆì§¸ë¡œ, ë¹„ìœ¨ì´ ì¦ê°€í•˜ëŠ” ë¶€ë¶„ì€ ë¶€ë‹´ì´ ë©ë‹ˆë‹¤. ì²« ë²ˆì§¸ë¡œ, ë©”ë””ì¼€ì´ë“œê°€ ì„±ì¥í•¨ì— ë”°ë¼ ì‚¬ì—… êµ¬ì„±ì˜ ë³€í™”ê°€ ìˆìŠµë‹ˆë‹¤. ì—¬ëŸ¬ë¶„ë„ ì•Œë‹¤ì‹œí”¼, ë©”ë””ì¼€ì´ë“œëŠ” MAì— ë¹„í•´ ë†’ì€ í˜œíƒ ë¹„ìœ¨ì„ ê°€ì§‘ë‹ˆë‹¤. ë‘ ë²ˆì§¸ë¡œ, IRAì˜ ì˜í–¥ìœ¼ë¡œ, ìˆ˜ìµ ì¦ê°€ì— ë”°ë¥¸ ì²­êµ¬ ì¦ê°€ë¡œ í˜œíƒ ë¹„ìœ¨ì´ ì¦ê°€í•©ë‹ˆë‹¤.</td></tr>
<tr><td>And third, incremental investments, which are important to the long term, but increase the benefit ratio in the near term.</td><td>ì„¸ ë²ˆì§¸ë¡œ, ì¥ê¸°ì ìœ¼ë¡œ ì¤‘ìš”í•˜ì§€ë§Œ ë‹¨ê¸°ì ìœ¼ë¡œ ì´ìµ ë¹„ìœ¨ì„ ì¦ê°€ì‹œí‚¤ëŠ” ì ì§„ì  íˆ¬ìê°€ ìˆìŠµë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">During a financial Q&A session, Ann Hynes from Mizuho inquired about the factors influencing the 2025 MLR (Medical Loss Ratio) guidance. Celeste Mellet responded by outlining the main drivers for changes in the MLR. Decreases in the ratio were attributed to exits from MA plans with high benefit ratios, adjustments in remaining plans, and a favorable calendar year in 2025. Conversely, increases in the MLR were due to a shift in business mix towards Medicaid, which has a higher benefit ratio, the impact of the Inflation Reduction Act (IRA) which raises the benefit ratio due to increased revenue and claims, and incremental investments that are expected to benefit the long term but increase the benefit ratio in the short term.</p>
    <hr style="margin:50px 0;">
    
</body></html>